Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | EML4 | Q9HC35 | 3/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ROS1 | P08922 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | MOK | Q9UQ07 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944784 | 1.00 | LRRK2 (0.36) | LRRK2GRM2CCNCCDK8EML4 | |
| SCHEMBL30206132 | 0.94 | LRRK2 (0.36) | LRRK2CCNCCDK8MOKEGFR | |
| SCHEMBL29173704 | 0.94 | LRRK2 (0.36) | LRRK2CCNCCDK8MOKEGFR | |
| SCHEMBL30206173 | 0.90 | LRRK2 (0.35) | LRRK2MOKEGFRKCNH2JAK2 | |
| SCHEMBL24944376 | 0.90 | LRRK2 (0.35) | LRRK2MOKEGFRKCNH2JAK2 | |
| SCHEMBL24944783 | 0.88 | LRRK2 (0.41) | LRRK2GRM2CCNCCDK8EML4 | |
| SCHEMBL24944442 | 0.88 | RET (0.37) | LRRK2EML4ALKRETROS1 | |
| SCHEMBL24944494 | 0.86 | LRRK2 (0.42) | LRRK2CCNCCDK8ALKEGFR | |
| Formic Acid SCHEMBL29173332 | 0.86 | LRRK2 (0.39) | LRRK2GRM2CCNCCDK8EML4 | |
| Formic Acid SCHEMBL30205467 | 0.86 | LRRK2 (0.39) | LRRK2GRM2CCNCCDK8EML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | claimed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | claimed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |